Skip to content
TB Alliance | Putting science to work for better, faster TB cures.
  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • Who we are
    • FAQ
    • Annual Report
  • Why New TB Drugs
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • TB Market Access Research
    • Child-Friendly Medicines
    • Pretomanid and the BPaL Regimen
    • Access to the BPaL Regimen
  • News
    • News
    • Publications
    • Voices of TB
    • Research Papers
    • Innovate to Eradicate
Donate
Donate
TB Alliance | Putting science to work for better, faster TB cures.
  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • Who we are
    • FAQ
    • Annual Report
  • Why New TB Drugs
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • TB Market Access Research
    • Child-Friendly Medicines
    • Pretomanid and the BPaL Regimen
    • Access to the BPaL Regimen
  • News
    • News
    • Publications
    • Voices of TB
    • Research Papers
    • Innovate to Eradicate
Donate
Donate
TB Alliance | Putting science to work for better, faster TB cures.
  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • Who we are
    • FAQ
    • Annual Report
  • Why New TB Drugs
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • TB Market Access Research
    • Child-Friendly Medicines
    • Pretomanid and the BPaL Regimen
    • Access to the BPaL Regimen
  • News
    • News
    • Publications
    • Voices of TB
    • Research Papers
    • Innovate to Eradicate
Donate
Donate
TB Alliance | Putting science to work for better, faster TB cures.
  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • Who we are
    • FAQ
    • Annual Report
  • Why New TB Drugs
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • TB Market Access Research
    • Child-Friendly Medicines
    • Pretomanid and the BPaL Regimen
    • Access to the BPaL Regimen
  • News
    • News
    • Publications
    • Voices of TB
    • Research Papers
    • Innovate to Eradicate
Donate
Donate

Seychelles

By TB Alliance / June 16, 2021
  • About
  • Why New TB Drugs
  • R&D
  • Access
  • News
New York: 80 Pine Street, 20th floor, New York, NY 10005 • +1 212 227 7540

Johannesburg: Spaces Atrium on 5th, 9th Floor, 5th Street, Sandton, Johannesburg, 2196, South Africa • +27 12 991 6328
Press Inquiries

Jess Wiggs
p | +1 646 616 8613
e | jessica.wiggs@tballiance.org
Jobs

View job openings
Join our mailing list

© 2025 The TB Alliance. All Rights Reserved. Report a Concern | Privacy Policy